Integrated opioid use disorder and HIV treatment: Rationale, clinical guidelines for addiction treatment, and review of interactions of antiretroviral agents and opioid agonist therapies

AIDS Patient Care and STDs

Volumn 24, Issue 1, 2010, Pages 15-22

  Batkis, Marcelo F ^a   Treisman, Glenn J ^a   Angelino, Andrew F ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; AMPRENAVIR; ATAZANAVIR; BUPRENORPHINE; DARUNAVIR; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; ENFUVIRTIDE; ETRAVIRINE; FOSAMPRENAVIR; INDINAVIR; LAMIVUDINE; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; MARAVIROC; METHADONE; NELFINAVIR; NEVIRAPINE; RALTEGRAVIR; RITONAVIR; SAQUINAVIR; STAVUDINE; TENOFOVIR; TENOFOVIR DISOPROXIL; TIPRANAVIR; UNCLASSIFIED DRUG; VIRAMMUNE; ZIDOVUDINE;

CLINICAL PRACTICE; DRUG DETOXIFICATION; HEALTH CARE PERSONNEL; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KNOWLEDGE; OPIATE ADDICTION; PATIENT CARE; REVIEW;

ANALGESICS, OPIOID; ANTI-HIV AGENTS; DRUG INTERACTIONS; HIV INFECTIONS; HUMANS; NARCOTICS; OPIOID-RELATED DISORDERS;

EID: 76649125217     PISSN: 10872914     EISSN: None     Source Type: Journal    
DOI: 10.1089/apc.2009.0242     Document Type: Review

References (36)

1. Department of Health and Human Services, Substance Abuse and Mental Health Services Administration. Results from the 2007 National Survey on Drug Use and Health: National Findings. September 2008. http:==oas.samhsa.gov (Last accessed November 5, 2009).
2. Bureau of Justice Statistics. Drug use and dependence, state and federal prisoners, 2004. October 2006. NCJ 213530.
3. Bureau of Justice Statistics. HIV in prisons, 2006. April 2008. NCJ 222179.
4. Hammett TM, Harmon MP, Rhodes W. The burden of infectios disease among inmates of and releases from US correctional facilities. Am J Public Health 2002;92:1789-1794.
5. Centers for Disease Control. HIV=AIDS Surveillance Report, 2006. Vol.18. Atlanta, GA: US Department of Health and Human Services, Centers for Disease Control 2008.
6. Turner BJ, Laine C, Cosler L, Hauck WW. Relationship of gender, depression, and health care delivery with antiretroviral adherence in HIV-infected drug users. J Gen Intern Med 2003;18:248-257.
7. Bouhnik A-D, Chesney M, Carrieri Patrizia, et al. Nonadherence among HIV-infected injecting drug users: The impact of social instability. J Acquir Immune Defic Syndr 2002;31(Suppl 3):S149-S153.
8. Korthuis PT, Zephyrin LC, Fleishman JA, et al. Healthrelated quality of life in HIV-infected patients: The role of substance use. AIDS Patient Care STDs 2008;22:859-867.
9. Waldron PR, Angelino A, Treisman GJ. Substance use disorders and HIV - common co-morbidities requiring coordinated management. Eur Infect Dis 2009;XX:44-49.
10. Hicks PL, Mulvey KP, Chander G, et al. The impact of illicit drug use and substance use treatment on adherence to HAART. AIDS Care 2007;19:1143-11140
11. Roux P, Carrieri MP, Villes V, et al. The impact of methadone or buprenorphine treatment and ongoing injection on highly active antiretroviral therapy (HAART) adherence: Evidence from the MANIF2000 cohort study. Addiction. 2008;103:1828-1836.
12. Palepu A, Tyndall MW, Joy R, et al. Antiretroviral adherence and HIV treatment outcomes among HIV=HCV co-infected injection drug users: The role of methadone maintenance therapy. Drug Alcohol Depend 2006;84:188-194.
13. Lucas GM, Mullen BA, Weidle PJ, Hader S, McCaul ME, Moore RD. Directly administered antiretroviral therapy in methadone clinics is associated with improved HIV outcomes, compared with outcomes among concurrent comparison groups. Clin Infect Dis 2006;42:1628-1635.
14. Nunn A, Zaller N, Dickman S, Trimbur C, Nijhhawan A, Rich JD. Methadone and buprenorphine prescribing and referral practices in US prison systems: Results from a nationwide survey. Drug Alcohol Depend 2009;105:83-88.
15. Lehman WEK, Fletcher BW, Wexler HK, Melnick G. Organizational factors and collaboration and integration activities in criminal justice and drug abuse treatment agencies. Drug Alcohol Depend 2009;103S:S65-S72.
16. Blankenship KM, Smoyer AB, Bray SJ, Mattocks K. Blackwhite disparities in HIV=AIDS: the role of drug policy and the corrections system. J Health Care Poor Underserved 2005;16:140-156.
17. Lombard F, Proescholdbell RJ, Cooper K, Musselwhite L, Quinlivan EB. Adaptations across clinical sites of an integrated treatment model for persons with HIV and substance abuse. AIDS Patient Care STDs 2009;23:631-638.
18. Mayfield D, McLeod G, Hall P. The CAGE questionnaire: A validation of a new alcoholism screening instrument. Am J Psychiatry 1974;131:1121-1123.
19. Skinner HA. The drug abuse screening test. Addict Behav 1982;7:363-371.
20. Prochaska JO, DiClemente CC, Norcross JC. In search of how people change. Applications to addictive behaviors. Am Psychol 1992;47:1102-1114.
21. Miller WR, Rollnick S. Motivational Interviewing: Preparing People to Change Addictive Behavior. New York: Guilford Press, 2002.
22. Albronda HF, Dean RL, Starkweather JA. Social class and psychotherapy. Arch Gen Psychiatry 1964;10:276-283.
23. Katz EC, Brown BS, Schwartz RP, Weintraub E, Barksdale W, Robinson R. Role induction: A method for enhancing early retention in outpatient drug-free treatment. J Consult Clin Psych 2004;72:227-234.
24. Miller WR, Benefield G, Tonigan JS. Enhancing motivation for change in problem drinking: a controlled comparison of two therapist styles. J Consult Clin Psych 1993;61:455-461.
25. Regier DA, Farmer ME, Rae DS, et al. Comorbidity of mental disorders with alcohol and other drug abuse: Results from the Epidemiologic Catchment Area (ECA) Study. JAMA 1990;264:2511-2518.
26. Sanchez-Craig M, Lei H. Disadvantages to imposing the goal of abstinence on problem drinkers: An empirical study. Br J Addict 1986;81:505-512.
27. Miller WR, Page AC. Warm turkey: Other routes to abstinence. J Subst Abuse Treat 1991;8:227-232.
28. Anstice S, Strike CJ, Brands B. Supervised methadone consumption: Client issues and stigma. Subst Use Misuse 2009;44:794-808.
29. Forman RF, Bovasso G, Woody G. Staff beliefs about addiction treatment. J Subst Abuse Treat 2001;21:1-9.
30. Zweben JE, Payte JT. Methadone maintenance in the treatment of opioid dependence: A current perspective. West J Med 1990;152:588-599.
31. Moody DE, Alburges ME, Parker RJ, Collins JM, Strong JM. The involvement of cytochrome P450 3A4 in the Ndemethylation of L-a-acetylmethadol (LAAM), norLAAM, and methadone. Drug Metab Dispos 1997;25:1347-1353.
32. Pérez Pons JC, Jornet Montañ a S, Bonet Esteve A. Interacciones farmacocinéticas entre metadona y antirretrovirales en pacientes infectados por el virus de la inmunodeficiencia humana. Med Cl?́n (Barc) 2001;119:224-229.
33. Totah R, Sheffels P, Roberts T, Whittington D, Thummel K, Kharasch ED. Role of CYP2B6 in stereoselective human methadone metabolism. Anesthesiology 2008;108:363-374.
34. De Fazio S, Gallelli L, De Siena A, De Sarro G, Scordo MG. Role of CYP3A5 in abnormal clearance of methadone. Ann Pharmacother 2008;42:893-897.
35. Picard N, Cresteil T, Djebli N, Marquet P. In vitro metabolism study of buprenorphine: Evidence for new metabolic pathways. Drug Metab Dispos 2005;33:689-695.
36. Eap CB, Buclin T, Baumann P. Interindividual variability of the clinical pharmacokinetics of methadone: Implications for the treatment of opioid dependence. Clin Pharmacokinet 2002;41:1153-1193.